2.685
전일 마감가:
$2.82
열려 있는:
$2.79
하루 거래량:
154.82K
Relative Volume:
0.26
시가총액:
$309.60M
수익:
$45.44M
순이익/손실:
$-35.43M
주가수익비율:
-7.8971
EPS:
-0.34
순현금흐름:
$-25.39M
1주 성능:
-7.71%
1개월 성능:
+10.00%
6개월 성능:
-30.18%
1년 성능:
-28.51%
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
MXCT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MXCT
Maxcyte Inc
|
2.685 | 309.60M | 45.44M | -35.43M | -25.39M | -0.34 |
![]()
ABT
Abbott Laboratories
|
132.25 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
104.61 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
382.56 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
83.51 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
75.41 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-11-29 | 개시 | Craig Hallum | Buy |
2021-10-15 | 재개 | Cowen | Outperform |
2021-08-24 | 개시 | BTIG Research | Buy |
2021-08-24 | 개시 | Cowen | Outperform |
2021-08-24 | 개시 | Stephens | Overweight |
2021-08-24 | 개시 | Stifel | Buy |
2021-08-24 | 개시 | Wedbush | Outperform |
2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Position Trimmed by Legal & General Group Plc - Defense World
MaxCyte Expands Stock Capital with New Share Issuance - TipRanks
Upward Trajectory: MaxCyte Inc (MXCT) Posts a Slidee, Closing at 2.84 - DWinneX
A stock that deserves closer examination: MaxCyte Inc (MXCT) - uspostnews.com
Renaissance Technologies LLC Has $1.17 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World
MaxCyte Announces AIM Delisting to Focus on NASDAQ - TipRanks
MaxCyte Inc (MXCT) requires closer examination - uspostnews.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - marketscreener.com
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Lifted by American Century Companies Inc. - Defense World
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Globe and Mail
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - Stocksregister
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
MaxCyte Expands Capital with New Stock Issuance - TipRanks
Charles Schwab Investment Management Inc. Decreases Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights - TipRanks
Bank of New York Mellon Corp Reduces Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맥스사이트 주식 (MXCT) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
자본화:
|
볼륨(24시간):